Search for a command to run...
<bold>Background:</bold> Triple therapy (long acting beta-2 agonist; LABA+long acting muscarinic antagonist; LAMA+inhaled corticosteroids; ICS) widely recommended in asthma treatment, but little is known about physician's opinions and behaviors on their real-life usage. <bold>Aims and objectives:</bold> The objective of the survey was to assess physicians' perceptions of the intensification of treatment regimes in not well-controlled asthma including ICS, LABA, LAMA, biologics, oral corticosteroids (OCS). <bold>Methods:</bold> A survey of 19 questions was distributed in Poland, Greece, Sweden, Slovenia, and Austria with the CATI-system platform using an electronic CAWI method. Pulmonologists, allergologists, GPs, and internal medicine specialists were invited. <bold>Results:</bold> 630 surveys were completed in Poland(57.6%), Greece(27%), Sweden(6.3%). Slovenia (5.4%), and Austria(3.7%). On the question: ‘To which patients with asthma would you use SITT?” physicians responded(%) in the following order: <table-wrap><object-id>erj;66/suppl_69/PA1417/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td>Question/country (%)</td><td>Poland</td><td>Greece</td><td>Austria</td><td>Sweden</td><td>Slovenia</td></tr><tr><td>Patients with coexisting asthma and COPD</td><td>89</td><td>92</td><td>78</td><td>95</td><td>100</td></tr><tr><td>Patients with chronic inflammation, persistent obstruction, lower FEV1, and frequent exacerbations</td><td>71</td><td>78</td><td>61</td><td>58</td><td>65</td></tr><tr><td>Patients who do not meet the criteria for biological therapy</td><td>67</td><td>62</td><td>48</td><td>35</td><td>47</td></tr><tr><td>Patients for whom high doses of ICS or oral steroids OCS are not recommended</td><td>59</td><td>52</td><td>35</td><td>58</td><td>47</td></tr><tr><td>Patients overusing short acting beta-2 agonist (SABA</td><td>54</td><td>49</td><td>35</td><td>48</td><td>38</td></tr><tr><td>Patients refusing to take oral medication or for whom it is not recommended</td><td>34</td><td>25</td><td>22</td><td>23</td><td>24</td></tr></tbody></table></table-wrap> <bold>Conclusions:</bold> There is a need to revise current asthma treatment guidelines towards implementation of SITT in steps 4/5 of GINA, before intensification of ICS, OCS, and biologics.